We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
FUJIFILM Irvine Scientific to Exclusively Distribute Chemically Defined Substrate for Stem Cell Culture
Cellnest® substrate enables optimal adhesion and proliferation of stem cells for cell and gene therapy research
SANTA ANA, Calif., September 29, 2020: FUJIFILM Irvine Scientific, Inc., today announced that it has become the exclusive, worldwide distributor of cellnest®, a recombinant peptide attachment substrate that provides optimal adhesion and proliferation of stem cells in chemically defined, animal component-free conditions. Cellnest was designed and manufactured by FUJIFILM Corporation, joining its vast portfolio of solutions that support life science applications and therapeutic innovation.
Attachment substrates mimic the extracellular matrix (ECM), a complex and dynamic environment in which cells reside in vivo, in cell culture and allow for the adhesion, expansion, and potential differentiation of stem cells. Unlike animal-derived components which can introduce unpredictability in results, the chemically defined, animal component-free formula of cellnest provides consistent results to researchers, and can smooths the regulatory path to commercialization. Cellnest is compatible with any adherent cell type that binds to the Arg-Gly-Asp (RGD) domain, an amino acid sequence within the extracellular matrix protein fibronectin that mediates cell attachment. It is an ideal companion product to FUJIFILM Irvine Scientific’s PRIME-XV portfolio of xeno-free and chemically defined media for stem cell culture, and is well suited for the attachment and growth of mesenchymal stem cells (MSCs).
“We are dedicated to accelerating the development and introduction of new offerings, including cellnest, to support our partners in advancing cell and gene therapy research,” said Yutaka Yamaguchi, General Manager, Life Science Strategic Business Office, FUJIFILM Holdings America Corporation, and Chairman and CEO, FUJIFILM Irvine Scientific. ”Leveraging the collective expertise and capabilities of our resources within the network of Fujifilm life science companies, enables us to provide innovative solutions for our partners, from discovery through to commercialization.”
For more information about cellnest, please visit: http://www.irvinesci.com/products/1063967-cellnest-recombinant-peptide
Image: Cellnest recombinant peptide attachment substrate
For a high-resolution image please contact lorna.cuddon@zymecommunications.com
About Fujifilm
FUJIFILM Irvine Scientific, Inc.
FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy, and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.
FUJIFILM Holdings
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.
Media Contacts
Lori Serles
FUJIFILM Irvine Scientific
Phone: (949) 261-7800 x145
Email: lori.serles@fujifilm.com
Lorna Cuddon
Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com
